Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MIM-D3 · 1 trial · 1 indication
Ocular surface damage
| Arm | Type | Description |
|---|---|---|
| 1% MIM-D3 Ophthalmic Solution | EXPERIMENTAL | - |
| 5% MIM-D3 Ophthalmic Solution | EXPERIMENTAL | - |
| Placebo Ophthalmic Solution | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MIM-D3 Ophthalmic Solution | DRUG | 28 Days, BID |
| Placebo Ophthalmic Solution | DRUG | 28 Days, BID |
Inclusion Criteria: 1. Be at least 18 years of age 2. Provide written informed consent 3. Have a reported history of dry eye 4. Have a history of use or desire to use eye drops for dry eye Exclusion Criteria: 1. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or activ...
MIM-D3 is an investigational small molecule being developed for the treatment of dry eye. It is formulated as an ophthalmic solution and is currently in clinical development for this condition.
MIM-D3 is being developed by BrainsWay Ltd. (NASDAQ: BWAY). The company is conducting clinical trials to evaluate the safety and efficacy of MIM-D3 ophthalmic solution for dry eye.
MIM-D3 is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities.
MIM-D3 has been studied in one completed Phase 2 clinical trial, NCT01257607, which evaluated the safety and efficacy of MIM-D3 ophthalmic solution for the treatment of dry eye. The trial enrolled 150 participants in the United States.
Yes, the Phase 2 trial of MIM-D3 was randomized, double-blind, and placebo-controlled. The study enrolled 150 participants aged 18 years and older, and it was completed in the United States.